Exploring the cutting edge of lifespan extension: Insights provided by Simone Gibertoni
The second series of the popular Brains of Wellbeing & Beauty series kicked off with a thought-provoking panel discussion, marking the first event in this year's lineup. The discussion, which took place in the first episode of the second series, was centred around the transformative impact of AI technologies on diagnostic tools and the future of holistic wellness strategies.
Leading the conversation was Simone Gibertoni, the CEO of Clinique La Prairie, who shared insights into the upcoming advancements in the longevity frontier. Gibertoni emphasised the integration of cutting-edge molecular tests and personalised precision medicine to optimise healthspan and biological aging.
Clinique La Prairie, under Gibertoni's leadership, is at the forefront of these advancements. Key innovations include the Glycans Chronic Inflammation Score, a proprietary molecular test measuring chronic inflammation and immune system health, and Ceramide Testing (CERT2 technology), an advanced biomarker test analysing ceramide levels in the bloodstream to assess cardiovascular risk years in advance.
Personalised genetic testing and DNA microbiota testing are also part of Clinique La Prairie's strategy, providing individualised insights into genetic predispositions and gut bacterial DNA, respectively. These tests aim to enable precision medicine approaches such as customised nutrition, treatment plans, and exercise regimens.
The discussions during the panel were set against the backdrop of the $2tn global wellness market, highlighting the growing importance of these advancements in the industry. The holistic yet data-driven approach combining molecular diagnostics, genetic profiling, and lifestyle factors is expected to accurately assess and enhance biological age beyond chronological age, a concept referred to as the "epigenetic youth capital."
The vision of precision longevity is not limited to Clinique La Prairie. It is a topic of broader industry discussions, such as at the St. Moritz Longevity Forum 2025, where Gibertoni speaks on how science, data, and holistic wellness converge to define the future landscape of longevity clinics.
Joining Gibertoni in the panel was HTSI editor Jo Ellison, adding a diverse perspective to the discussions. The second series of Brains of Wellbeing & Beauty, as always, features conversations with innovators and health practitioners, promising another enlightening journey into the world of wellness and beauty.
The panel discussion, led by Simone Gibertoni, the CEO of Clinique La Prairie, delved into the role of artificial intelligence in diagnostic tools and the future of holistic wellness strategies, especially incorporating cutting-edge molecular tests and personalised precision medicine, which are key innovations being implemented at Clinique La Prairie. The integration of technology, science, and health-and-wellness, as discussed in the panel, aligns with the firm's strategy that also includes personalised genetic testing and DNA microbiota testing, aiming to provide customised nutrition, treatment plans, and fitness-and-exercise regimens, positioning Clinique La Prairie at the forefront of the transformative impact of AI on the global wellness market valued at $2tn.
